• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

The PIONEER-HF Trial: Sacubitril-valsartan linked to superior outcomes in acute decompensated heart failure

byJames RoebkerandDayton McMillan
February 12, 2019
in Cardiology, Emergency
Reading Time: 3 mins read
The PIONEER-HF Trial: Sacubitril-valsartan linked to superior outcomes in acute decompensated heart failure
Share on FacebookShare on TwitterShare on LinkedIn

1. Among patients hospitalized for acute decompensated heart failure with reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduced N-terminal pro-B type natriuretic peptide (NT-proBNP) greater than treatment with enalapril.

2. There was no significant difference in the rate of worsening renal function, hyperkalemia, symptomatic hypotension, or angioedema between either treatment group.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: While the landmark PARADIGM-HF trial demonstrated that the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan had superior clinical outcomes in patients with HFrEF compared to the angiotensin-converting enzyme inhibitor (ACEi) enalapril, patients with acute decompensated HF were excluded. Given this population comprises a large part of clinical practice, the PIONEER-HF trial was conducted to analyze the efficacy and safety of ARNI therapy in patients with HFrEF hospitalized for acute decompensated HF. The authors reported a significantly greater reduction in NT-proBNP concentration, the primary outcome, in patients treated with sacubitril-valsartan compared to enalapril. Among key safety outcomes, there was no significant difference in the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema between the sacubitril-valsartan and enalapril groups. The results of this trial extend the conclusions drawn from PIONEER-HF, and suggest ARNI therapy is a safe and effective strategy in HFrEF patients who present with acute decompensated HF.

This was a multicenter, randomized trial with a large and diverse patient population. It provided high level evidence of ARNI therapy in the inpatient HFrEF population, which was previously absent. The trial was limited by the high rate of medication discontinuation and high percentage of missing data. Furthermore, translation to clinical practice is limited by the strict requirements for sacubitril-valsartan initiation (including a 36-hour medication washout period) set by the authors, which may increase hospital stay. Future studies will need to look at potential outcome benefits of treatment with sacubitril-valsartan in patients with decompensated heart failure.

Click to read the study in the NEJM (New England Journal of Medicine)

RELATED REPORTS

A medical care at home program following hospitalization with acute decompensated heart failure may offer a safe and effective alternative to continued hospitalization

Higher doses of heart failure guideline-directed medical therapy prescribed to patients with acute heart failure admission are associated with better outcomes

Click to read an accompanying editorial in NEJM

Relevant Reading: Angiotensin-neprilysin inhibition versus enalapril in heart failure

In-Depth [randomized controlled trial]: This was a multicenter trial that randomized 881 patients with HFrEF to sacubitril-valsartan (n=440) or enalapril (n=441) therapy. Primary outcome data, the time-averaged proportional change in the NT-proBNP concentration from baseline through weeks 4 and 8, was available for 349 (79.3%) of patients in the sacubitril-valsartan group and 348 (78.9%) in the enalapril group. Key safety outcomes included incidences of worsening renal function (increase in creatinine ³0.5 mg/dL and decrease in estimated glomerular filtration rate ³25%), hyperkalemia (³5.5 mmol/L), symptomatic hypotension, and angioedema.

Excluding discontinuation due to death, the trial medication was stopped early in 87 (19.6%) patients in the sacubitril-valsartan group and 90 (20.3%) patients in the enalapril group. The time-averaged reduction in NT-proBNP concentration obtained at weeks 4 and 8 was significantly greater in the sacubitril-valsartan group than enalapril group (percent change, -46.7% vs. -25.3%, respectively; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). This result was evident by week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). There was no difference between the two treatment groups in the rates of worsening renal function (relative risk [RR] between sacubitril-valsartan vs. enalapril, 0.93; 95% CI, 0.67 to 1.28), hyperkalemia (RR, 1.25; 95% CI, 0.84 to 1.84), symptomatic hypotension (RR, 1.18; 95% CI, 0.85 to 1.64), or angioedema (RR, 0.17; 95% CI, 0.02 to 1.38).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

 

 

Tags: acute decompensated heart failureARNIEnalaprilsacubitril-valsartan
Previous Post

2 Minute Medicine Rewind February 11, 2019

Next Post

Paracetamol plus ibuprofen significantly reduces post-operative morphine use in total hip arthroplasty patients

RelatedReports

Heart failure collage: an engraved heart with teal ventricles above a folded patchwork quilt, a teacup and house slippers
Cardiology

A medical care at home program following hospitalization with acute decompensated heart failure may offer a safe and effective alternative to continued hospitalization

July 24, 2026
Cardiology

Higher doses of heart failure guideline-directed medical therapy prescribed to patients with acute heart failure admission are associated with better outcomes

February 2, 2024
StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

February 10, 2022
Heart attack collage: a heart with one coronary artery pinched by a blue band, a calm woman, a phone handset and an aspirin
Cardiology

Effectiveness of sacubitril-valsartan in post-myocardial infarction management

February 3, 2022
Next Post

Paracetamol plus ibuprofen significantly reduces post-operative morphine use in total hip arthroplasty patients

USPSTF: Counseling interventions likely to prevent perinatal depression

Symptomatic and non-symptomatic heart failure associated with increased postoperative mortality in non-cardiac elective surgery

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.